Intercept Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Intercept Pharmaceuticals is Jerry Durso, benoemd in Jan2021, heeft een ambtstermijn van 2.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.46M, bestaande uit 16% salaris en 84% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde € 919.29K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 8.7 jaar.

Belangrijke informatie

Jerry Durso

Algemeen directeur

US$4.5m

Totale compensatie

Percentage CEO-salaris	16.0%
Dienstverband CEO	2.8yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	8.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jerry Durso's beloning veranderd ten opzichte van Intercept Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$57m
Jun 30 2023	n/a	n/a	-US$159m
Mar 31 2023	n/a	n/a	-US$173m
Dec 31 2022	US$4m	US$715k	-US$175m
Sep 30 2022	n/a	n/a	-US$202m
Jun 30 2022	n/a	n/a	-US$115m
Mar 31 2022	n/a	n/a	-US$120m
Dec 31 2021	US$8m	US$691k	-US$136m
Sep 30 2021	n/a	n/a	-US$144m
Jun 30 2021	n/a	n/a	-US$193m
Mar 31 2021	n/a	n/a	-US$231m
Dec 31 2020	US$4m	US$600k	-US$273m
Sep 30 2020	n/a	n/a	-US$321m
Jun 30 2020	n/a	n/a	-US$339m
Mar 31 2020	n/a	n/a	-US$347m
Dec 31 2019	US$4m	US$573k	-US$345m
Sep 30 2019	n/a	n/a	-US$335m
Jun 30 2019	n/a	n/a	-US$314m
Mar 31 2019	n/a	n/a	-US$318m
Dec 31 2018	US$3m	US$541k	-US$309m
Sep 30 2018	n/a	n/a	-US$333m
Jun 30 2018	n/a	n/a	-US$341m
Mar 31 2018	n/a	n/a	-US$352m
Dec 31 2017	US$4m	US$441k	-US$360m

Compensatie versus markt: De totale vergoeding ($USD 4.46M ) Jerry } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Jerry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jerry Durso (55 yo)

2.8yrs

Tenure

US$4,455,463

Compensatie

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jerome Durso	President	2.8yrs	US$4.46m	0.12% € 919.3k
Andrew Saik	Chief Financial Officer	2.4yrs	US$1.39m	0.055% € 408.4k
Jared Freedberg	General Counsel	2.8yrs	US$1.31m	0.13% € 1.0m
Linda Richardson	Executive VP & Chief Commercial Officer	2.8yrs	US$1.34m	0.040% € 296.4k
M. Berrey	President of Research & Development and Chief Medical Officer	2.4yrs	US$1.61m	0.068% € 503.0k
Rocco Venezia	Chief Accounting Officer & Treasurer	2.7yrs	US$856.23k	0.061% € 451.6k
Nareg Sagherian	Executive Director of Global Investor Relations	1.9yrs	geen gegevens	geen gegevens
David Ford	Chief Human Resources Officer	6.5yrs	US$1.91m	0.036% € 266.8k
Mark Pruzanski	Founder	2.8yrs	US$6.43m	1.48% € 11.0m
Paul Nitschmann	Senior Vice President of Regulatory Affairs	no data	geen gegevens	geen gegevens
Kathleen Munster	Chief Quality Officer & SVP of Technical Operations	less than a year	geen gegevens	geen gegevens
Michael Blash	Senior Vice President of Corporate Affairs	less than a year	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van I4P wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jerome Durso	President	2.5yrs	US$4.46m	0.12% € 919.3k
Mark Pruzanski	Founder	21.8yrs	US$6.43m	1.48% € 11.0m
Daniel Bradbury	Independent Chairman	7.3yrs	US$327.39k	0.056% € 417.8k
Glenn Sblendorio	Independent Director	9.8yrs	US$332.39k	0.056% € 416.0k
Luca Benatti	Independent Director	9.3yrs	US$327.39k	0.061% € 452.2k
Srinivas Akkaraju	Independent Director	11.1yrs	US$317.39k	0.091% € 672.2k
Gino Santini	Lead Independent Director	8yrs	US$337.39k	0.057% € 419.5k
Alan Hofmann	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Scott L. Friedman	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Massimo Pinzani	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Aldo Roda	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Keith Gottesdiener	Independent Director	7.3yrs	US$322.39k	0.059% € 438.6k

8.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van I4P wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.7 jaar).

Intercept Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Intercept Pharmaceuticals, Inc. Appoints Rocco Venezia as Chief Accounting Officer

Intercept Pharmaceuticals, Inc. Appoints Dagmar Rosa-Bjorkeson to its Board of Directors

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings released: US$0.066 loss per share (vs US$3.04 loss in 3Q 2022)

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.68 loss in 2Q 2022)

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.77 loss per share (vs US$1.13 loss in 1Q 2022)

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast to breakeven in 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast to breakeven in 2024

Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings released: US$0.58 loss per share (vs US$1.22 loss in 1Q 2021)

Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Intercept Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Pomerantz Law Firm Announces the Filing of A Class Action Against Intercept Pharmaceuticals, Inc

Forecast to breakeven in 2024

Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH

Intercept Pharmaceuticals, Inc. Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$2.02 loss in 3Q 2020)

Intercept Pharmaceuticals, Inc. announced a financing transaction

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$1.92 loss in 2Q 2020)

Intercept Pharmaceuticals, Inc. to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021

Independent Director Daniel Welch has left the company

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2021

First quarter 2021 earnings released: US$1.22 loss per share (vs US$2.86 loss in 1Q 2020)

CFO, Treasurer & Principal Accounting Officer has left the company

Intercept Pharmaceuticals, Inc. Appoints Rocco Venezia as Chief Accounting Officer

Chief Medical Officer has left the company

New 90-day low: €19.65

Full year 2020 earnings released: US$8.34 loss per share (vs US$10.89 loss in FY 2019)

Revenue misses expectations

Intercept Pharmaceuticals, Inc. Appoints Dagmar Rosa-Bjorkeson to its Board of Directors

Intercept Pharmaceuticals, Inc. Announces Management Changes

Intercept Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Intercept Pharmaceuticals, Inc. Announces Resignation of Richard Kim as President, U.S. Commercial & Strategic Marketing, Effective February 15, 2021

Intercept Pharmaceuticals, Inc. Appoints Jared M. Freedberg as General Counsel and Secretary